206 related articles for article (PubMed ID: 21082185)
1. Atrial-selective drugs for treatment of atrial fibrillation.
Ravens U; Christ T
Herzschrittmacherther Elektrophysiol; 2010 Dec; 21(4):217-21. PubMed ID: 21082185
[TBL] [Abstract][Full Text] [Related]
2. Atria-selective antiarrhythmic drugs in need of alliance partners.
Peyronnet R; Ravens U
Pharmacol Res; 2019 Jul; 145():104262. PubMed ID: 31059791
[TBL] [Abstract][Full Text] [Related]
3. In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.
Aguilar-Shardonofsky M; Vigmond EJ; Nattel S; Comtois P
Biophys J; 2012 Mar; 102(5):951-60. PubMed ID: 22404917
[TBL] [Abstract][Full Text] [Related]
4. Atrial-selective K
Ravens U
Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
[TBL] [Abstract][Full Text] [Related]
5. [New developments in the antiarrhythmic therapy of atrial fibrillation].
Simon H; Simon Demel K; Ritscher G; Turschner O; Brachmann J
Herzschrittmacherther Elektrophysiol; 2010 Dec; 21(4):212-6. PubMed ID: 21107985
[TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic therapy in atrial fibrillation.
Ravens U
Pharmacol Ther; 2010 Oct; 128(1):129-45. PubMed ID: 20624425
[TBL] [Abstract][Full Text] [Related]
7. Can inhibition of IKur promote atrial fibrillation?
Burashnikov A; Antzelevitch C
Heart Rhythm; 2008 Sep; 5(9):1304-9. PubMed ID: 18774108
[TBL] [Abstract][Full Text] [Related]
8. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
[TBL] [Abstract][Full Text] [Related]
9. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
Singh BN
J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
[TBL] [Abstract][Full Text] [Related]
10. Theoretical possibilities for the development of novel antiarrhythmic drugs.
Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.
Burashnikov A; Belardinelli L; Antzelevitch C
Heart Rhythm; 2015 Apr; 12(4):836-44. PubMed ID: 25546810
[TBL] [Abstract][Full Text] [Related]
12. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat.
Blaauw Y; Gögelein H; Tieleman RG; van Hunnik A; Schotten U; Allessie MA
Circulation; 2004 Sep; 110(13):1717-24. PubMed ID: 15364815
[TBL] [Abstract][Full Text] [Related]
13. Atrial selectivity of antiarrhythmic drugs.
Ravens U; Poulet C; Wettwer E; Knaut M
J Physiol; 2013 Sep; 591(17):4087-97. PubMed ID: 23732646
[TBL] [Abstract][Full Text] [Related]
14. Atrial-selective sodium channel block for the treatment of atrial fibrillation.
Burashnikov A; Antzelevitch C
Expert Opin Emerg Drugs; 2009 Jun; 14(2):233-49. PubMed ID: 19466903
[TBL] [Abstract][Full Text] [Related]
15. Antifibrillatory agents and potassium channels in the atria: pore block versus channel trafficking.
McEwen DP; Martens JR
Mol Interv; 2009 Apr; 9(2):79-86. PubMed ID: 19401540
[TBL] [Abstract][Full Text] [Related]
16. Effects of a highly selective acetylcholine-activated K+ channel blocker on experimental atrial fibrillation.
Machida T; Hashimoto N; Kuwahara I; Ogino Y; Matsuura J; Yamamoto W; Itano Y; Zamma A; Matsumoto R; Kamon J; Kobayashi T; Ishiwata N; Yamashita T; Ogura T; Nakaya H
Circ Arrhythm Electrophysiol; 2011 Feb; 4(1):94-102. PubMed ID: 21156770
[TBL] [Abstract][Full Text] [Related]
17. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
Singh BN; Mody FV; Lopez B; Sarma JS
Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
[TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.
Li D; Sun H; Levesque P
Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):64-75. PubMed ID: 19149545
[TBL] [Abstract][Full Text] [Related]
19. AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog.
Burashnikov A; Zygmunt AC; Di Diego JM; Linhardt G; Carlsson L; Antzelevitch C
J Cardiovasc Pharmacol; 2010 Jul; 56(1):80-90. PubMed ID: 20386458
[TBL] [Abstract][Full Text] [Related]
20. Atrial-selective sodium channel blockers: do they exist?
Burashnikov A; Antzelevitch C
J Cardiovasc Pharmacol; 2008 Aug; 52(2):121-8. PubMed ID: 18670368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
